Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study

Abstract excerpt

ABSTRACT: The recalcitrant nature of triple-negative breast cancer (TNBC) calls for novel treatments. Acetalax (oxyphenisatin acetate) and bisacodyl, which have been and are extensively used orally as laxatives, have recently been reported to exhibit selective antiproliferative activity when incubated with cancer cells and xenograft models. Here, we show that they are both preferentially active in TNBC cell...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bioactive Compounds and Antitumor Agents
• Share to Cancer, Stress, Anesthesia, and Immune Response
• Share to Ion Channels and Receptors